Scarica l'app Stockscreener
118.05
2.10%
2.43
Dopo l'orario di chiusura:
118.05
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
Axsome Therapeutics, Exelixis, Incyte Among 20 New Stocks On IBD's Premier Watchlists - Investor's Business Daily
Form 4 Incyte Corporation For: 7 July By Investing.com - Investing.com Canada
INCY Maintained by RBC Capital -- Price Target Raised to $99.00 - GuruFocus
Incyte Corporation (INCY) Completes Acquisition of Vega Therapeu - GuruFocus
Incyte Corp. stock underperforms Monday when compared to competitors - MarketWatch
Incyte (INCY) Completes Acquisition of Vega Therapeutics - GuruFocus
Incyte completes $1.25B acquisition of Vega Therapeutics - grafa.com
Incyte completes $1.25B Vega Therapeutics acquisition - Investing.com
Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio - Business Wire
Incyte Shares Rise on EPS Growth, Lifted Guidance, Expansion - Yahoo Finance
Incyte Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Truist Financial Maintains Incyte(INCY.US) With Hold Rating - Moomoo
Incyte (INCY): Truist Raises the Price Target to $105 as a Government Settlement Adds $246 Million to Net Sales - Insider Monkey
Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Incyte Corp gains 16% in a week, boosted by str... - Pluang
Incyte stock: Is INCY outperforming the healthcare sector? - MSN
INCY Stock Hits 52-Week High on Regulatory Updates for Opzelura - Yahoo Finance
Incyte (INCY) Surges 5.8%: Is This an Indication of Further Gains? - Yahoo Finance
H.C. Wainwright reiterates Incyte stock rating on EU label expansion By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Incyte stock rating on EU label expansion - Investing.com
INCY Reiterated by HC Wainwright & Co. -- Price Target Maintained at $140 - GuruFocus
Incyte (INCY) Stock After 66% One-Year Rally Is The Market Too Optimistic Now - Yahoo Finance
Incyte (INCY) Wins EU Backing For Opzelura As Pipeline Data Builds Across Four Drugs - Yahoo Finance
INCY Maintains by UBS -- Price Target Raised to $113 - GuruFocus
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
UBS raises Incyte stock price target to $113 on biotech recovery By Investing.com - Investing.com Australia
UBS raises Incyte stock price target to $113 on biotech recovery - Investing.com Nigeria
Why is Incyte stock surging today? - Investing.com
Incyte receives positive CHMP opinion for Opzelura in moderate atopic dermatitis - grafa.com
Incyte (INCY) Receives Positive CHMP Opinion for Opzelura Approval - GuruFocus
Incyte Corporation stock hits 52-week high at 112.32 USD - Investing.com
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis - BioSpace
Incyte stock jumps on positive EU review for eczema cream - Investing.com
Star Therapeutics' bleeding-disorder drug VGA039 gets full Phase 1/2 data spotlight - Stock Titan
(ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis - Business Wire
Incyte Corp (INCY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Incyte extends hematology data at EHA, shares track NASDAQ biotech peers - Ad-hoc-news.de
Japan Approves Incyte Lymphoma Therapy, Expanding DLBCL Options - MyChesCo
INCY Reiterates by HC Wainwright & Co. -- Price Target Maintained at $140 - GuruFocus
H.C. Wainwright reiterates Incyte stock rating on Medicaid settlement - Investing.com
H.C. Wainwright reiterates Incyte stock rating on Medicaid settlement By Investing.com - Investing.com Canada
Key deals this week: GSK, Incyte, Ingredion, OpenAI, and more - MSN
Incyte nears $2B deal for blood disorder drug developer Star Therapeutics: FT - MSN
INCY Maintained by Truist Securities -- Price Target Raised to $105 - GuruFocus
This ConocoPhillips Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Sahm
Truist raises Incyte stock price target to $105 on VWD outlook - Investing.com UK
Incyte reports tafasitamab combo benefit in Phase III FrontMIND study - MSN
Incyte Corporation’s Stock Price Soars to $103.66, Marking a Robust 5.54% Uptick - Smartkarma
Why is Incyte stock gaining today? - Investing.com
Incyte Corporation (INCY) Reaches Settlement with CMS Over Medic - GuruFocus
1.17%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):